Watch Whole Prescribing Info OPDIVO® (nivolumab) is indicated for the treatment of Grownup patients with classical Hodgkin lymphoma (cHL) which includes relapsed or progressed immediately after autologous hematopoietic stem mobile transplantation (HSCT) and brentuximab vedotin or soon after 3 or even more traces of systemic therapy that features a